Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.
Grant E. Pickering, MBA, currently serves as executive-in-residence at Kleiner Perkins Caufield & Byers, a venture capital firm located in Menlo Park, Calif. He has previously served as president and CEO of Juvaris BioTherapeutics and Pharmada, as well as in managing and development positions at Dendreon, Johnson & Johnson, GlaxoSmithKline and Algos Pharmaceutical.
Christopher S. Henney, Ph.D., D.Sc., currently serves as chairman of the board of directors of Oncothyreon and Anthera Pharmaceuticals, and vice-chairman of the board of directors of Cyclacel Pharmaceuticals—all development-stage biotechnology companies. Previously, he served as chairman and CEO of Dendreon, chairman of SGX Pharmaceuticals and co-founded both Immunex and ICOS.